TherapeuticsMD, Inc. (TXMD) Position Trimmed by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC cut its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,470,766 shares of the company’s stock after selling 562,914 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 1.14% of TherapeuticsMD worth $13,070,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares in the last quarter. Managed Account Services Inc. boosted its holdings in shares of TherapeuticsMD by 5.5% during the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after purchasing an additional 1,322 shares during the last quarter. Traynor Capital Management Inc. boosted its holdings in shares of TherapeuticsMD by 14.0% during the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after purchasing an additional 2,799 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of TherapeuticsMD by 6.5% during the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock valued at $298,000 after purchasing an additional 3,441 shares during the last quarter. Institutional investors and hedge funds own 72.54% of the company’s stock.

Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) traded down $0.03 on Wednesday, reaching $5.87. 4,050,100 shares of the company’s stock traded hands, compared to its average volume of 2,910,469. TherapeuticsMD, Inc. has a 52 week low of $3.50 and a 52 week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. During the same period in the previous year, the firm posted ($0.13) earnings per share. The business’s revenue for the quarter was down 19.7% compared to the same quarter last year. equities research analysts anticipate that TherapeuticsMD, Inc. will post -0.37 EPS for the current year.

Several analysts have recently issued reports on the stock. Deutsche Bank AG assumed coverage on shares of TherapeuticsMD in a research report on Friday, July 21st. They set a “buy” rating and a $10.00 target price on the stock. Cantor Fitzgerald restated a “buy” rating and set a $33.00 target price on shares of TherapeuticsMD in a research report on Monday, September 4th. BidaskClub upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. Morgan Stanley started coverage on shares of TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective on the stock. Finally, Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $10.00 price objective on shares of TherapeuticsMD in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. TherapeuticsMD presently has an average rating of “Buy” and an average price target of $14.72.

ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD, Inc. (TXMD) Position Trimmed by Gilder Gagnon Howe & Co. LLC” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/11/15/therapeuticsmd-inc-txmd-position-trimmed-by-gilder-gagnon-howe-co-llc.html.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of TherapeuticsMD stock in a transaction that occurred on Wednesday, August 30th. The stock was purchased at an average price of $5.99 per share, with a total value of $29,950.00. Following the completion of the acquisition, the director now directly owns 3,555 shares in the company, valued at approximately $21,294.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 23.92% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply